news

Our latest
Press Releases & Updates

Latest press releases

RetinAI and Retina Consultants of America Join Forces to build the Most Comprehensive U.S.-based Real World Evidence Database in Ophthalmology

RetinAI Medical AG and Retina Consultants of America (RCA) forge a strategic partnership to revolutionize Ophthalmology data. Leveraging RetinAI's advanced AI technologies and RCA's expansive clinic network, this alliance is set to develop the largest Real World Evidence (RWE) U.S.-based database in the field.

RetinAI Joins Forces with Boehringer Ingelheim to Advance Novel Treatments for Patients with Geographic Atrophy using Artificial Intelligence

RetinAI Medical AG has announced a partnership with Boehringer Ingelheim to improve patient outcomes in geographic atrophy (GA). RetinAI's AI tools for identifying novel biomarkers will be used to analyze Boehringer Ingelheim's imaging datasets from clinical studies and real-world evidence to identify additional biomarkers and predictors of disease progression. This partnership aims to accelerate the development of novel treatments and enable earlier and more precise diagnosis, contributing to Boehringer Ingelheim's vision of preventing vision loss and blindness caused by retinal diseases.

RetinAI’s AI Algorithms Enrich Clinical Research and Improve Patient Care

RetinAI Medical AG has announced the acceptance of five abstracts for poster presentations at the Association for Research in Vision and Ophthalmology (ARVO) conference taking place from April 23rd to 26th, 2023 in New Orleans. These studies highlight the potential of RetinAI’s Discovery platform and its certified and research use only (RUO) AI models to revolutionize healthcare decisions, improve patient care, help accelerate clinical trials, and drive better decisions for patient management.

RetinAI and Geographic Atrophy (GA) Expert Working Group partner to enable data collaboration and automated analysis of GA biomarkers for CAM using Discovery

RetinAI partnered with the Classification of Atrophy Meeting (CAM) Group in December 2022 to provide RetinAI’s Discovery® platform to the expert working group, consisting of more than 30 members, to facilitate peer-to-peer data collaboration and perform accelerated, automated biomarker analysis of real-world datasets of geographic atrophy (GA) patients. 

Latest updates

Machine learning can predict anti-VEGF treatment demand in a Treat-and-Extend regimen for patients with nAMD, DME and RVO associated ME

2 new Posters in ARVO 2021 Virtual

We are very excited of our team and collaborators presenting 2 posters in ARVO 2021! One Poster on 'Longitudinal analysis of Retinal Pigment Epithelium Atrophy progression using an automated segmentation algorithm' providing segmentation analysis over 5 years using deep learning,
and a poster on 'Automated fovea and optic disc detection in the presence of occlusions in Fundus SLO Images'.

New publication on TVST - Automated quantification of pathological fluids in neovascular age-related degeneration, and it's repeatability using deep learning

In this peer reviewed publication, we develop a reliable algorithm for the automated identification, localization, and volume measurement of exudative manifestations in neovascular age-related macular degeneration (nAMD), including intraretinal (IRF), subretinal fluid (SRF), and pigment epithelium detachment (PED), using a deep-learning approach. The deep-learning algorithm can simultaneously acquire a high level of performance for the identification and volume measurements of IRF, SRF, and PED in nAMD, providing accurate and repeatable predictions. Including layer segmentation during training and squeeze-excite block in the network architecture were shown to boost the performance. Source: Mantel et al. , TVST 2021, 10 (17) - https://doi.org/10.1167/tvst.10.4.17 Authors: Irmela Mantel; Agata Mosinska; Ciara Bergin; Maria Sole Polito; Jacopo Guidotti; Stefanos Apostolopoulos; Carlos Ciller; Sandro De Zanet

Translation Vision Science and Technology

RetinAI receives ISO 13485:2016 certification

Retinai has just received the ISO 13485 certification, a recognition awarded by regulatory bodies and necessary for companies willing to develop & commercialise Medical Devices. RetinAI Discovery, our platform for medical image and data management in ophthalmology, is now getting ready to be commercialised to clinics as a medical device. We are extremely proud of the team for achieving the certification!

Contact us for more informations! We are happy to hear from you!